# Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

> **NCT02858362** · PHASE2 · TERMINATED · sponsor: **Summit Therapeutics** · enrollment: 43 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Ezutromid

## Key facts

- **NCT ID:** NCT02858362
- **Lead sponsor:** Summit Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2018-04-11
- **Final completion:** 2018-09-11
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of efficacy in Cohorts 1 and 2.
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858362, "Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02858362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*